牛乳腺炎市场机会、成长动力、产业趋势分析及 2025-2034 年预测

2024 年全球牛乳腺炎市场价值为 20 亿美元，预计 2025 年至 2034 年的复合年增长率为 6.3%。这一扩张受到几个关键因素的推动，包括牛乳腺炎发病率的上升、人们对动物健康的认识的提高以及全球对乳製品的需求不断增长。随着乳製品行业不断扩大经营规模以满足不断增长的全球需求，对有效的疾病管理解决方案的需求也日益加剧。

农民和乳製品生产商更加重视改善牛隻的健康和生产力，这推动了对先进诊断工具和创新治疗方案的投资。此外，对永续乳牛养殖的高度关注促使市场参与者探索非抗生素疗法，如益生菌和疫苗，以解决乳房炎问题，同时减轻抗菌素抗药性。这些全行业的努力正在培育强劲的市场格局，使牛乳腺炎治疗成为兽医学的关键成长领域。

市场分为药品和诊断。医药部门包括抗生素、疫苗和其他旨在对抗乳牛感染的治疗解决方案。青霉素和头孢菌素等抗生素仍广泛用于乳房炎治疗，而乳房内灌注疗法的持续创新正在提高治疗效果。随着乳製品生产商寻求快速有效的解决方案，製药公司正致力于改进药物配方，以降低抗生素抗药性并提高受感染牛隻的康復率。同时，由于早期检测方法的采用日益增多，诊断领域正在稳步增长，从而可以及时干预并更好地管理畜群。

牛乳腺炎市场根据类型进一步分为临床乳房炎和亚临床乳房炎。 2024 年，临床乳房炎占了 55% 的市场份额，这主要是因为其症状明显且对牛奶产量有重大影响。临床乳房炎会造成直接的经济损失，因此成为酪农和兽医的首要任务。人们对这种疾病的认识不断提高，以及可用的治疗选择范围不断扩大，正在推动市场的成长。同时，对抗生素抗药性的担忧正推动该行业寻求替代治疗方法。非抗生素疗法，包括益生菌、疫苗和草药配方，作为符合监管变化和消费者对无抗生素乳製品需求的可持续解决方案，正受到越来越多的关注。

2024 年美国牛乳腺炎产业价值为 6.83 亿美元，反映了近年来的持续成长。该国牲畜数量庞大，加上对高品质牛奶的需求不断增加，推动了乳牛养殖和兽医服务的扩张。由于高度重视牛隻的健康，酪农正在采用更为复杂的治疗方案和精准畜牧技术。预计这一趋势将进一步加速牛乳腺炎管理的进步，巩固美国市场在兽医创新和乳製品生产力方面的领导地位。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 全球乳製品消费量不断成长
    • 乳腺炎检测技术的进展
    • 动物健康意识不断增强
  • 产业陷阱与挑战
    • 治疗费用高
    • 抗生素抗药性问题
• 成长潜力分析
• 监管格局
• 未来市场趋势
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按产品，2021 - 2034 年

• 主要趋势
• 製药
  • 抗生素
  • 疫苗
  • 其他药品
• 诊断

第六章：市场估计与预测：按类型，2021 - 2034 年

• 主要趋势
• 临床乳腺炎
• 亚临床性乳腺炎

第七章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 乳房内
• 系统性

第八章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 兽医医院和诊所
• 诊断实验室
• 其他最终用途

第九章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Advanced Animal Diagnostics
• Boehringer Ingelheim
• Ceva
• DeLaval
• Elanco
• Heilsaa
• HIPPRA
• ImmuCell Corporation
• Merck & Co
• Norbrook
• Virbac
• Zoetis

The Global Bovine Mastitis Market, valued at USD 2 billion in 2024, is projected to grow at a CAGR of 6.3% from 2025 to 2034. This expansion is driven by several key factors, including the rising incidence of bovine mastitis, increasing awareness about animal health, and a growing demand for dairy products worldwide. As the dairy industry continues to scale up operations to meet the surging global demand, the need for effective disease management solutions has intensified.

Farmers and dairy producers are placing greater emphasis on improving cattle health and productivity, which is fueling investments in advanced diagnostic tools and innovative treatment solutions. Additionally, the heightened focus on sustainable dairy farming is prompting market players to explore non-antibiotic therapies, such as probiotics and vaccines, to address mastitis concerns while mitigating antimicrobial resistance. These industry-wide efforts are fostering a robust market landscape, making bovine mastitis treatment a critical area of growth in veterinary medicine.

The market is segmented into pharmaceuticals and diagnostics. The pharmaceutical segment includes antibiotics, vaccines, and other treatment solutions aimed at combating infections in dairy cattle. Antibiotics such as penicillin and cephalosporin remain widely used for mastitis treatment, while ongoing innovations in intramammary infusion therapies are enhancing treatment efficacy. With dairy producers seeking fast and effective solutions, pharmaceutical companies are focusing on improving drug formulations to reduce antibiotic resistance and improve recovery rates in affected cattle. Meanwhile, the diagnostics segment is experiencing steady growth due to the increasing adoption of early detection methods, allowing for timely intervention and better herd management.

The bovine mastitis market is further categorized by type into clinical and subclinical mastitis. In 2024, clinical mastitis accounted for 55% of the market, primarily due to its visible symptoms and the significant impact on milk production. The immediate economic losses associated with clinical mastitis make it a top priority for dairy farmers and veterinarians. Growing awareness about the condition, along with a wider range of available treatment options, is supporting market growth. At the same time, concerns over antimicrobial resistance are pushing the industry towards alternative treatment approaches. Non-antibiotic therapies, including probiotics, vaccines, and herbal formulations, are gaining traction as sustainable solutions that align with regulatory shifts and consumer demand for antibiotic-free dairy products.

The U.S. Bovine Mastitis Industry was valued at USD 683 million in 2024, reflecting consistent growth over recent years. The country's large livestock population, coupled with increasing demand for high-quality milk, is driving expansion in dairy farming and veterinary services. With a strong emphasis on cattle health, dairy farmers are adopting more sophisticated treatment solutions and precision livestock farming technologies. This trend is expected to further accelerate advancements in bovine mastitis management, reinforcing the U.S. market's leadership in veterinary innovation and dairy productivity.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising global dairy consumption
    • 3.2.1.2 Advancements in mastitis detection technologies
    • 3.2.1.3 Growing awareness of animal health
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Antibiotic resistance concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Pharmaceutical
  • 5.2.1 Antibiotics
  • 5.2.2 Vaccines
  • 5.2.3 Other pharmaceuticals
• 5.3 Diagnostics

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Clinical mastitis
• 6.3 Sub-clinical mastitis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Intra-mammary
• 7.3 Systemic

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals and clinics
• 8.3 Diagnostic laboratories
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Advanced Animal Diagnostics
• 10.2 Boehringer Ingelheim
• 10.3 Ceva
• 10.4 DeLaval
• 10.5 Elanco
• 10.6 Heilsaa
• 10.7 HIPPRA
• 10.8 ImmuCell Corporation
• 10.9 Merck & Co
• 10.10 Norbrook
• 10.11 Virbac
• 10.12 Zoetis